SUPN - Supernus Pharmaceuticals, Inc.
| Previous Close | 37.91 |
| Open | 38.15 |
| Bid | 37.42 x 1000 |
| Ask | 37.45 x 2900 |
| Day's Range | 36.77 - 38.80 |
| 52 Week Range | 34.90 - 61.25 |
| Volume | 378,355 |
| Avg. Volume | 589,793 |
| Market Cap | 1.946B |
| Beta (3Y Monthly) | 0.82 |
| PE Ratio (TTM) | 20.38 |
| EPS (TTM) | 1.83 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 59.70 |
- Motley Fool•6 hours ago
3 Top Biotech Stocks to Buy in December
Find out why our team of healthcare experts believe that these biotechs are great buys right now.
- Investor's Business Daily•5 days ago
This Index Of Leading Stocks Falls Into A Bear Market As Boeing Stings Dow Jones
After a one-day break, stock indexes continued to drop Thursday, while the IBD 50 index of leading stocks fell into a bear market.
- Reuters•5 days ago
Supernus Pharma's ADHD treatment fails to impress; shares fall
Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals. The drug, SPN-812, is a non-stimulant and belongs to the same class of medicine as Eli Lilly and Co's Strattera and Shire Plc's Intuniv. Analysts on average said that SPN-812 has failed to stand out from existing treatment options for ADHD.
- Motley Fool•5 days ago
Here's Why Supernus Pharmaceuticals Is Sinking Today
Sometimes good news just isn't good enough.
Markit•5 days agoSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc NASDAQ NMS:SUPN
- GlobeNewswire•5 days ago
Consolidated Research: 2018 Summary Expectations for TD Ameritrade Holding, Supernus Pharmaceuticals, Akcea Therapeutics, Dell Technologies, iRobot, and Pegasystems — Fundamental Analysis, Key Performance Indications
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•5 days ago
The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering
Here's a roundup of top developments in the biotech space over the past 48 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 4) Johnson & Johnson (NYSE: JNJ ) Eli Lilly And Co (NYSE: ...
- Reuters•5 days ago
Supernus Pharma's ADHD treatment succeeds in two late-stage studies
Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder met the main goal of reducing disorder symptoms in children in two late-stage studies. ...
- GlobeNewswire•5 days ago
Supernus Announces Positive Results from Two Phase III Studies For SPN-812 in Children with ADHD
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from each of two pivotal Phase III studies of SPN-812 in children for the treatment of attention deficit hyperactivity disorder (ADHD). Both trials were successful in achieving the primary endpoint, with SPN-812, at daily doses of 100 mg and 200 mg in study P301 and 200 mg and 400 mg in study P303.
- GlobeNewswire•6 days ago
Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on Thursday, December 6, 2018, at approximately 7:00 a.m. ET, it will issue a press release announcing the results of its two Phase III studies for SPN-812 in patients 6-11 years old, for the treatment of attention deficit hyperactivity disorder (ADHD). Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
- ACCESSWIRE•7 days ago
Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...
Markit•8 days agoSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on November 29.
- Investor's Business Daily•11 days ago
Stock Market Stages Bullish Reversal To Cap Week With Big Gains
The stock market shrugged off early weakness Friday to finish with solid gains. It sought direction as traders look ahead to this weekend's G20 summit.
- ACCESSWIRE•12 days ago
Today's Research Reports on Trending Tickers: Heron Therapeutics and Supernus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Wall Street closed up on Wednesday as dovish comments made by Federal Reserve Chairman Jerome Powell boosted investor optimism. According to the Chairman, Jerome Powell, “Interest rates are still low by historical standards, and they remain just below the broad range of estimates of the level that would be neutral for the economy — that is, neither speeding up nor slowing down growth.” The Dow Jones Industrial Average surged 2.5 percent to close at 25,366.43, while the S&P 500 Index jumped 2.3 percent to close at 2,743.79. “Markets wanted to hear Powell say that there is no preset course of rates, that he is mindful of weaknesses in the global economy, and, most importantly, that tariffs have altered the calculus of the future of the U.S. economy,” Cox said.
Markit•17 days agoSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The net inflows of $586 million over the last one-month into ETFs that hold SUPN are among the lowest of the last year and appear to be slowing.
- Simply Wall St.•26 days ago
What Should Investors Know About Supernus Pharmaceuticals Inc’s (NASDAQ:SUPN) Future?
After Supernus Pharmaceuticals Inc’s (NASDAQ:SUPN) earnings announcement on 30 September 2018, analysts seem fairly confident, as a 28% increase in profits is expected in the upcoming year, though this is Read More...
- InvestorPlace•28 days ago
5 Sizzling Small-Cap Stocks to Buy Today
Small-cap stocks have long beaten their larger rivals in the returns department. For starters, there’s plenty of growth to be had in small-cap stocks. Secondly, thanks to their domestic focus, small-cap stocks directly benefit more from the rising U.S. economy and the Republican tax plan.
- GlobeNewswire•last month
Supernus to Present at Three November Healthcare Conferences
ROCKVILLE, Md., Nov. 07, 2018 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Thomson Reuters StreetEvents•last month
Edited Transcript of SUPN earnings conference call or presentation 7-Nov-18 2:00pm GMT
Q3 2018 Supernus Pharmaceuticals Inc Earnings Call
- Motley Fool•last month
3 Top Biotech Stocks to Buy in November
If you don't consider adding these biotech stocks to your portfolio this month, you could wind up missing out on an opportunity.
- Zacks•last month
Supernus Pharmaceuticals (SUPN) Tops Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 20.93% and 2.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Supernus: 3Q Earnings Snapshot
The Rockville, Maryland-based company said it had profit of 52 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue
Total revenue of $103.0 million, a 28% increase over 2017Net product sales of $100.2 million, a 28% increase over 2017Operating earnings of $37.5 million, a 68% increase over.
Markit•last monthSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- GlobeNewswire•2 months ago
Recent Analysis Shows Supernus Pharmaceuticals, GDS HOLDINGS, Golden Ocean Group, Golar LNG, Endo International plc, and 51job Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
